Kallistratos G, Evangelou A, Seferiadis K, Vezyraki P, Barboutis K
Nephron. 1985;41(3):217-22. doi: 10.1159/000183586.
In 40 healthy persons, 11 nondialyzed uremic patients and 27 dialyzed uremic patients, of whom 4 also had cancer, the selenium concentration in serum was determined. The mean serum selenium concentration in healthy persons was 13.6 +/- 0.8 micrograms/dl, in nondialyzed patients 11.9 +/- 1.9 micrograms/dl and in dialyzed uremic patients 11.3 +/- 1.0 micrograms/dl. There was a significant statistical difference between healthy persons and uremic patients (p less than 0.001), but not between dialyzed and nondialyzed uremic patients. The subgroup of cancer patients on hemodialysis also had low serum selenium concentrations. The possible role of low selenium levels as one of the factors responsible for the increased incidence of malignancy in patients with chronic renal failure is supported by several facts such as: low serum selenium levels detected in patients with malignant diseases; the higher cancer incidence in inhabitants of low-selenium areas, and the known ability of selenium to inhibit many types of experimental carcinogenesis.
对40名健康人、11名未透析的尿毒症患者和27名已透析的尿毒症患者(其中4人还患有癌症)的血清硒浓度进行了测定。健康人的平均血清硒浓度为13.6±0.8微克/分升,未透析患者为11.9±1.9微克/分升,已透析的尿毒症患者为11.3±1.0微克/分升。健康人与尿毒症患者之间存在显著统计学差异(p<0.001),但已透析和未透析的尿毒症患者之间无差异。接受血液透析的癌症患者亚组血清硒浓度也较低。低硒水平作为慢性肾衰竭患者恶性肿瘤发病率增加的因素之一,其可能作用得到了以下几个事实的支持:恶性疾病患者血清硒水平低;低硒地区居民癌症发病率较高,以及已知硒具有抑制多种实验性致癌作用的能力。